Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Long-Term Investments (2022 - 2026)

Alx Oncology Holdings' Long-Term Investments history spans 2 years, with the latest figure at $35.4 million for Q4 2023.

  • On a quarterly basis, Long-Term Investments rose 112.05% to $35.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $35.4 million, a 112.05% increase, with the full-year FY2023 number at $35.4 million, up 112.05% from a year prior.
  • Long-Term Investments hit $35.4 million in Q4 2023 for Alx Oncology Holdings, up from $6.4 million in the prior quarter.
  • Over the last five years, Long-Term Investments for ALXO hit a ceiling of $35.4 million in Q4 2023 and a floor of $6.4 million in Q3 2023.